What is self.co?
Established in 2015 by Gintautas Gylys and Tautvydas Gylys, Self.co is a pioneering digital health and diagnostics company dedicated to helping individuals understand and effectively manage allergy-like symptoms. The firm leverages proprietary molecular testing technology, including advanced microarray-based assays. These assays analyze allergens and food sensitivities from a small blood sample, which can be conveniently collected at home or through partner clinics. This innovative approach positions Self.co at the forefront of personalized health diagnostics, offering accessible and accurate insights into complex sensitivities.
How much funding has self.co raised?
self.co has raised a total of $3M across 2 funding rounds:
Unspecified
$1.4M
Grant
$1.6M
Unspecified (2025): $1.4M with participation from Coinvest Capital and Iron Wolf Capital
Grant (2025): $1.6M led by Innovation Agency Lithuania
Key Investors in self.co
Coinvest Capital
Coinvest Capital is a venture capital fund that co-invests with business angels and other private funds in startups, focusing on enhancing the startup ecosystem in Lithuania. With a committed capital of EUR 44.3 million, the fund aims to fill funding gaps and strengthen the business angel community by investing in sectors of strategic importance, including GreenTech, Life Sciences, and Defence.
Iron Wolf Capital
Iron Wolf Capital is a venture capital firm that invests in exceptional founders building global AI and deep tech startups in the Baltics and diaspora. They typically lead or co-lead investment rounds ranging from EUR 0.5-2M. Since 2019, they have invested in over 20 startups across various sectors including photonics, robotics, AI, education, pharma, and agritech.
Innovation Agency Lithuania
Inovacijų Agentūra Viskas apie verslą offers a wide range of services aimed at supporting and developing existing and emerging businesses and innovations in Lithuania. This grant likely supports the company's research and development efforts.
What's next for self.co?
With the recent major strategic investment and a robust total funding history of $3M, Self.co is poised for significant expansion. The company's focus on proprietary molecular testing technology for allergy-like symptoms places it in a high-growth segment of the digital health market. Future strategic initiatives will likely involve scaling its testing capabilities, expanding its clinical partnerships, and enhancing its direct-to-consumer offerings. The backing from Coinvest Capital and Iron Wolf Capital, both active in deep tech and life sciences, suggests a strategic alignment with the company's technological advancements and market potential. Continued investment in R&D and market penetration will be key to solidifying its leadership position.
See full self.co company page
